Manufacturers of 10 Drugs Slated for Medicare Price Negotiation Spent Billions More on Buybacks, Dividends and Executive Compensation than R&D

"The industry tells us that Medicare price negotiations will make it hard to research and develop new drugs. What they leave out is that many are already spending far more to make their executives and shareholders rich than on R&D," said Peter Maybarduk, Access to Medicines program director at Public Citizen. "When these corporations complain about the impact of price negotiations on innovation, we should be deeply skeptical."…

https://www.commondreams.org/newswire/manufacturers-of-10-drugs-slated-for-medicare-price-negotiation-spent-billions-more-on-buybacks-dividends-and-executive-compensation-than-rd